Overview
NICE is unable to make a recommendation on mepolizumab (Nucala) for treating severe hypereosinophilic syndrome in adults because GSK did not provide an evidence submission.
Last reviewed: 29 November 2022
Next review: We will review this decision if the company decides to make a submission.